Eating nuts may help colon cancer survive

Share This Post

According to the CALGB 8903 study published in the Journal of Clinical Oncology, patients with stage III colon cancer who eat at least 2 servings of nuts per week have higher disease-free survival (DFS) and overall survival (OS). The association between total nut intake and improved outcomes is consistent among other known or suspected risk factors for cancer recurrence and death.

Dr. Charles S. Fuchs of the Yale Cancer Center and colleagues wrote: “This prospective study of patients with stage III colon cancer shows that a diet with increased nut consumption is associated with a significant reduction in cancer recurrence and mortality. Although we observed The results of sex studies cannot determine causality, but the results further support diet and lifestyle as modifiable risk factors for patients with colon cancer. “

This study conducted a 6.5-year follow-up survey of 826 colon cancer patients treated with surgery and chemotherapy. The results showed that people who consumed at least two ounces of nuts per week had a 42% increase in disease-free survival and an increase in overall survival. 57%.

The researchers said: “Further analysis of the cohort showed that the disease-free survival of participants who consumed nuts significantly increased. Nuts include almonds, walnuts, hazelnuts, cashews, walnuts, etc. On the contrary, peanuts are actually a type of bean food . These results are consistent with other observational studies that show that a range of health behaviors, including increasing physical activity, maintaining a healthy weight, and lower intake of sugar and sweet drinks can increase the survival rate of colon cancer. “

The findings emphasize the importance of diet and lifestyle factors in the survival of colon cancer. In addition, the researchers emphasized that the study emphasized the connection between biological mechanisms of not only colon cancer but also certain chronic diseases, such as type 2 diabetes, which worsens the disease.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy